Medical Back Problems without MCC DRG Reimbursement Guide

DRG 552 covers inpatient stays for medical management of back problems without a Major Complication or Comorbidity, focusing on nonsurgical care and evaluation. Correct assignment is important for inpatient reimbursement because it determines the Medicare payment rate tied to resource use and case-mix reporting.

DRG 552 Overview

DRG 552 (Medical Back Problems without Major Complication or Comorbidity) groups inpatient admissions for nonoperative medical management of acute or chronic back pain and related nonsurgical spinal conditions when no Major Complication or Comorbidity is present. This Diagnosis-Related Group captures cases where treatment is primarily medical, may include diagnostic imaging and pain management, and excludes admissions with higher-severity comorbid conditions. It matters for Medicare payment because the assignment determines the bundled payment rate and influences hospital case-mix and resource-use reporting. Proper classification affects reimbursement and hospital financial planning for medically managed spine care.

DRG 552 Overview

Benchmarking across major commercial payers shows mean allowed amounts ranging from about $8.8K (BCBS) to $16K (Cigna), with payer medians between $8.7K and $16K; the overall payer range spans roughly $4.5K to $32K. The widest spread appears between Anthem’s minimum and maximum ($390 to $32K), indicating substantial variability across commercial agreements. See the table and chart below for payer-specific percentiles and distributions.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($9.0k), average submitted covered charges ($45.9k), average Medicare payment amount ($6.9k), and total discharges (46.2k).

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$9K	$46K	$6.9K	46K

Patient Population

The DRG 552 population is mixed but tilts toward working-age and commercially insured patients rather than being predominantly Medicare-age. Many discharges for this DRG occur in a non-elderly cohort covered by private/commercial payers, with a meaningful but smaller share covered by Medicare. Overall, the payer mix reflects both commercial and Medicare utilization rather than being exclusive to Medicare-age beneficiaries.

Alaska Benchmarks

Alaska’s DRG 552 benchmark means span from $15K (Blue Cross Blue Shield and Anthem) up to $23K (Cigna), reflecting a modest-but-visible payer spread. Cigna’s mean of $23K stands out as the most notable deviation above the state cluster and trends higher than many national medians. Reference the table and chart below for payer-specific distributions.

Key Insights for Alaska

The highest paying payer in Alaska for DRG 552 is Cigna (mean $23K); the lowest are Blue Cross Blue Shield and Anthem (both mean $15K).
Alaska’s payer range is relatively wide (from $15K to $23K), with Cigna notably above the Alaska medians and above typical national medians for several payers.
The state’s lower-bound payers at $15K sit below many national payer medians, indicating a meaningful downward deviation versus national rates.

Acute nonoperative intervention trials: studies testing short-term inpatient management strategies such as optimized analgesic protocols, early multimodal pain control regimens, or standardized physical therapy initiation for patients admitted with acute exacerbations of non-surgical back pain. These trials enroll adults hospitalized primarily for medical back problems without major comorbid complications and compare time-to-pain-control, opioid-sparing effects, and length of stay across intervention arms. Findings inform clinicians on best practices for acute symptom control and help payers assess cost-effectiveness of in-hospital pathways that could reduce resource use and readmissions.
Comparative effectiveness and care pathway studies: pragmatic randomized or observational studies comparing different care pathways (for example, expedited outpatient referral plus focused inpatient education versus extended inpatient conservative management) for patients with subacute or chronic nonoperative back conditions admitted for symptom flare. These studies focus on functional outcomes, return-to-work, utilization of imaging or speciality consultations, and subsequent healthcare use over 30–90 days in heterogeneous adult populations without major complications. Results are relevant to hospitals and payers because they identify which inpatient-to-outpatient transition strategies yield better functional recovery and lower downstream costs for this DRG.
Post-discharge outcomes and readmission risk research: cohort studies and predictive-modeling research that track patient-reported pain, functional status, medication use, and 30- to 90-day readmission or ED visit rates after discharge for medical back problems without major complications. These investigations often evaluate social determinants, comorbid mental health or substance-use factors, and adherence to discharge plans to identify modifiable drivers of poor outcomes. Such evidence helps providers tailor discharge planning and helps payers develop targeted case management or bundled-payment approaches to reduce avoidable utilization associated with this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$9K	$46K	$6.9K	46K

Patient Population

Alaska Benchmarks

Key Insights for Alaska

The highest paying payer in Alaska for DRG 552 is Cigna (mean $23K); the lowest are Blue Cross Blue Shield and Anthem (both mean $15K).
Alaska’s payer range is relatively wide (from $15K to $23K), with Cigna notably above the Alaska medians and above typical national medians for several payers.
The state’s lower-bound payers at $15K sit below many national payer medians, indicating a meaningful downward deviation versus national rates.

Acute nonoperative intervention trials: studies testing short-term inpatient management strategies such as optimized analgesic protocols, early multimodal pain control regimens, or standardized physical therapy initiation for patients admitted with acute exacerbations of non-surgical back pain. These trials enroll adults hospitalized primarily for medical back problems without major comorbid complications and compare time-to-pain-control, opioid-sparing effects, and length of stay across intervention arms. Findings inform clinicians on best practices for acute symptom control and help payers assess cost-effectiveness of in-hospital pathways that could reduce resource use and readmissions.
Comparative effectiveness and care pathway studies: pragmatic randomized or observational studies comparing different care pathways (for example, expedited outpatient referral plus focused inpatient education versus extended inpatient conservative management) for patients with subacute or chronic nonoperative back conditions admitted for symptom flare. These studies focus on functional outcomes, return-to-work, utilization of imaging or speciality consultations, and subsequent healthcare use over 30–90 days in heterogeneous adult populations without major complications. Results are relevant to hospitals and payers because they identify which inpatient-to-outpatient transition strategies yield better functional recovery and lower downstream costs for this DRG.
Post-discharge outcomes and readmission risk research: cohort studies and predictive-modeling research that track patient-reported pain, functional status, medication use, and 30- to 90-day readmission or ED visit rates after discharge for medical back problems without major complications. These investigations often evaluate social determinants, comorbid mental health or substance-use factors, and adherence to discharge plans to identify modifiable drivers of poor outcomes. Such evidence helps providers tailor discharge planning and helps payers develop targeted case management or bundled-payment approaches to reduce avoidable utilization associated with this DRG.

Medical Back Problems without MCC: Inpatient Reimbursement Overview

Sign up for drg 552 policy alerts

DRG 552 Overview

Medical Back Problems without MCC: Inpatient Reimbursement Overview

Sign up for drg 552 policy alerts

DRG 552 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

References